AbbVie to ring in 2013 as an independent drugmaker

AbbVie has its final stamp of approval. Abbott Laboratories' ($ABT) directors endorsed the pharma unit's spinoff Wednesday, allowing AbbVie to ring in the new year as an independent company.Abbott shareholders will receive one share of AbbVie's common stock for each Abbott share they own. AbbVie's shares will hit New Year's Day, with trading expected to begin on the New York Stock Exchange when markets reopen Jan. 2. Ticker symbol: ABBV. Story

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.